Review Question - QID 215031

Researchers are conducting a study to evaluate the impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors as first-line agents in patients with newly diagnosed diabetes mellitus. Investigators prospectively collect a hemoglobin A1c (HbA1c) measurement in each study participant (if the initial diagnosis was made using HbA1c, then that value was used). Patients are then prescribed empagliflozin monotherapy. HbA1c measurements are obtained every 3 months, and additional glycemic agents are added at the treating physician’s discretion. Major endpoints are mortality, major cardiac events, and stroke at 1-year follow-up. The HbA1c measurements at study entry for the first 10 participants are shown in Figure A. The next 2 participants have HbA1c measurements of 10.4% and 12.6%. Which of the following measures of central tendency (with respect to these HbA1c measurements) is most likely to remain the same after the addition of these 2 participants?